The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis

Overview

Journal Curr Cardiol Rev

Publisher Bentham Science Publishers

Specialty Cardiology & Vascular Diseases

Date 2024 Jan 24

PMID 38265377

Authors

Hamza Salim

Basel Musmar

Motaz Saifi

Mohammed Ayyad

Mohammed Ruzieh

Jehad Azar

Zaher Nazzal

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide. Polypills, containing various combinations of medications for primary and secondary CVD prevention, have been developed to enhance medication adherence and reduce the healthcare burden of CVD. However, their effectiveness compared to usual care remains uncertain.

Objective: This meta-analysis aimed to evaluate the effects of polypills on cardiovascular risk factors, major adverse cardiovascular events (MACE), and medication adherence.

Methods: We conducted a comprehensive search for large-scale randomized controlled trials and observational studies comparing the effects of polypills versus usual care on CVD risk factors and events. Outcomes included changes in systolic and diastolic blood pressure (SBP, DBP), lipid profiles, occurrence of MACE, and medication adherence.

Results: The use of polypills led to a statistically significant yet clinically modest reduction in SBP (mean difference -1.47 mmHg, 95% CI: -2.50 to -0.44, p<0.01) and DBP (mean difference- 1.10 mmHg, 95% CI: -1.68 to -0.51, p< 0.01) compared to usual care. Polypills also showed a significant reduction in the risk of MACE (RR: 0.86, 95% CI: 0.77 -0.95, p<0.01). There was a non-significant reduction in LDL and HDL levels. Adherence to medication improved by up to 17% in polypill users compared to those on usual care (p < 0.01). A multivariable metaregression analysis suggested that adherence may be the underlying factor responsible for the observed effect of the polypills on blood pressure.

Conclusion: Polypills were found to significantly reduce SBP, DBP and MACE. An improvement in medication adherence was also observed among polypill users, which might be responsible for the significant reduction in SBP observed users. Future research might benefit from exploring a more personalized approach to the composition of polypills, which could reveal a more clinically significant impact of increased adherence on CVD outcomes.

Citing Articles

High Hypoperfusion Intensity Ratio Is Independently Associated with Very Poor Outcomes in Large Ischemic Core Stroke.

Yedavalli V, Salim H, Lakhani D, Balar A, Mei J, Luna L Clin Neuroradiol. 2024; 35(1):131-139.

PMID: 39373942 DOI: 10.1007/s00062-024-01463-7.

Assessing multilevel barriers to hydroxyurea adherence in youth with sickle cell disease using pharmacy-based refill records.

Smaldone A, Manwani D, Aygun B, Appiah-Kubi A, Smith-Whitley K, Green N Pediatr Blood Cancer. 2024; 71(9):e31170.

PMID: 38975794 PMC: 11268999. DOI: 10.1002/pbc.31170.

References

Segar M, Patel K, Vaduganathan M, Caughey M, Jaeger B, Basit M . Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. Diabetologia. 2021; 64(7):1583-1594. PMC: 10535363. DOI: 10.1007/s00125-021-05426-2. View

Lonn E, Bosch J, Teo K, Pais P, Xavier D, Yusuf S . The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010; 122(20):2078-88. DOI: 10.1161/CIRCULATIONAHA.109.873232. View

Sergienko I, Ansheles A, Drapkina O, Gornyakova N, Zubareva M, Shepel R . ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk. Ter Arkh. 2019; 91(4):90-98. DOI: 10.26442/00403660.2019.04.000104. View

Neutel J, Bestermann W, Dyess E, Graff A, Kursun A, Sutradhar S . The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2009; 11(1):22-30. PMC: 8673228. DOI: 10.1111/j.1751-7176.2008.00058.x. View

de Cates A, Farr M, Wright N, Jarvis M, Rees K, Ebrahim S . Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014; (4):CD009868. PMC: 4083498. DOI: 10.1002/14651858.CD009868.pub2. View

Hennawi H, Talal Ashraf M, Zohaib M, Khan M, Khan I, Muhammadzai H . Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Curr Probl Cardiol. 2023; 48(8):101735. DOI: 10.1016/j.cpcardiol.2023.101735. View

Zeymer U, Junger C, Zahn R, Bauer T, Bestehorn K, Senges J . Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. Curr Med Res Opin. 2011; 27(8):1563-70. DOI: 10.1185/03007995.2011.590969. View

Sadeghi M, Askari A, Bostan F, Heidari A, Ghasemi G, Tabatabaei G . Medication Adherence With Polypill in Cardiovascular Disease and High-Risk Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Involving 7364 Participants. Curr Probl Cardiol. 2023; 49(1 Pt A):102061. DOI: 10.1016/j.cpcardiol.2023.102061. View

Kim W, Chang K, Cho E, Ahn J, Yu C, Cho K . A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. J Clin Hypertens (Greenwich). 2020; 22(2):261-269. PMC: 8029832. DOI: 10.1111/jch.13774. View

10.

Kandil O, Motawea K, Aboelenein M, Shah J . Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022; 9:880054. PMC: 9046936. DOI: 10.3389/fcvm.2022.880054. View

11.

Donner A, Klar N . Issues in the meta-analysis of cluster randomized trials. Stat Med. 2002; 21(19):2971-80. DOI: 10.1002/sim.1301. View

12.

Castellano J, Pocock S, Bhatt D, Quesada A, Owen R, Fernandez-Ortiz A . Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022; 387(11):967-977. DOI: 10.1056/NEJMoa2208275. View

13.

Elley C, Gupta A, Webster R, Selak V, Jun M, Patel A . The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS One. 2013; 7(12):e52145. PMC: 3526586. DOI: 10.1371/journal.pone.0052145. View

14.

Lafeber M, Grobbee D, Schrover I, Thom S, Webster R, Rodgers A . Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2014; 181:193-9. DOI: 10.1016/j.ijcard.2014.11.176. View

15.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

16.

Bahiru E, de Cates A, Farr M, Jarvis M, Palla M, Rees K . Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2017; 3:CD009868. PMC: 6464321. DOI: 10.1002/14651858.CD009868.pub3. View

17.

Mostaza J, Suarez-Fernandez C, Cosin-Sales J, Gomez-Huelgas R, Brotons C, Araujo F . Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial. BMC Cardiovasc Disord. 2022; 22(1):560. PMC: 9773517. DOI: 10.1186/s12872-022-03013-w. View

18.

Marazzi G, Pelliccia F, Campolongo G, Cacciotti L, Massaro R, Poggi S . Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial. Int J Cardiol. 2016; 222:885-887. DOI: 10.1016/j.ijcard.2016.07.163. View

19.

Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee D . An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One. 2011; 6(5):e19857. PMC: 3102053. DOI: 10.1371/journal.pone.0019857. View

20.

Richard Hobbs F, Gensini G, John Mancini G, Manolis A, Bauer B, Genest J . International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil. 2009; 16(4):472-80. DOI: 10.1097/HJR.0b013e32832b63f5. View